The Cytel Blog: Perspectives on Enquiry & Evidence

Most of us are familiar with the concept of platform clinical trials as they have gained popularity in the recent..

Early stage Phase 2 clinical trials are often designed as multi-stage single arm trials, which quickly identify..

C-Suite and R&D Decision-Makers are always striving to make evidence-driven decisions. Yet the rules by which evidence..

  We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In..

  In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at..

As part of Cytel's new Trial Innovations Webinar Series, Pat Mitchell, Statistical Science Director at AstraZeneca..

 Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early..

 At the recent CMO Summit East  James ( Jim) Bolognese, Cytel’s Senior Director of Strategic Consulting, and Lou..

    Cost of pharmaceutical development and R&D productivity is an ongoing industry concern, consistently discussed in..